Trial Profile
A Phase II Study of Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Dec 2023
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Carcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 24 Oct 2023 According to Results presented at the 48th European Society for Medical Oncology Congress, If at least 2 responses were observed among 16 evaluable pts, the trial would proceed to the 25-patient second stage.
- 24 Oct 2023 Results (n=25) presented at the 48th European Society for Medical Oncology Congress
- 23 Jun 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2026.